Investigational drug · Phase 3
Fimasartan
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Essential Hypertension.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
67
Any phase or sponsor naming "Fimasartan"
First trial start
2022
Nov 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Fimasartan", any sponsor or status.
Conditions studied
As listed on its trial records.
- Essential Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Fimasartan" as an intervention, largest first.
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort StudyNot yet recruiting
First Teaching Hospital of Tianjin University of Traditional Chinese MedicineAcademic, hospital or other
NCT07262710 · 13,656 participants (planned) · Start Dec 1, 2025 · Primary completion Aug 1, 2026
Drug: angiotensin converting enzyme inhibitors; Calcium Channel Blockers and 1 more · For: Post-stroke Pneumonia
- A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and DyslipidemiaCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT04554953 · 10,877 participants · Start Apr 13, 2020 · Primary completion Nov 3, 2021
Drug: Combination drug containing fimasartan and statins · For: Hypertension and Dyslipidemia
Sites: Gwangju, South Korea
- Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension PatientsPivotal-lookingCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT00922480 · 506 participants · Start Dec 2008 · Primary completion Jul 2009
Drug: Fimasartan; Losartan (Control) · For: Hypertension
Boryung Pharmaceutical Co., LtdIndustry
NCT01518998 · 420 participants · Start Aug 2011 · Primary completion Oct 2013
Drug: Fimasartan , Amlodipine, Placebo · For: Hypertension
Sites: Seoul, South Korea
- Fimasartan Achieving SBP Target (FAST) StudyPivotal-lookingCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT02495324 · 369 participants · Start Jun 2015 · Primary completion May 2017
Drug: Placebo; Fimasartan and 2 more · For: Essential,Hypertension
Sites: Seoul, South Korea; Incheon, South Korea; Bucheon-si, South Korea · 8 sites in all
- A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of FimasartanPivotal-lookingCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT02620306 · 351 participants · Start Feb 11, 2016 · Primary completion Dec 23, 2019
Drug: Fimsartan 60mg~120mg; Fimsartan 60mg~120mg and 2 more · For: Chronic Kidney Disease
Sites: Seoul, South Korea
- A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential HypertensionPivotal-lookingCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT01672476 · 293 participants · Start Apr 2012 · Primary completion Mar 2013
Drug: Placebo; Valsartan and 1 more · For: Hypertension
Sites: Seoul, South Korea
- The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential HypertensionPivotal-lookingCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT01135212 · 290 participants · Start Apr 2010 · Primary completion Apr 2011
Drug: Fimasartan 60mg; Fimasartan 120mg and 1 more · For: Hypertension
Sites: Daegu, South Korea
- Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential HypertensionPivotal-lookingCompleted
Stendhal Americas, S.A.Industry
NCT02466490 · 272 participants · Start Apr 2013 · Primary completion Feb 2014
Drug: Fimasartan; Fimasartan; Hydrochlorothiazide · For: Hypertension, Essential
Sites: México, Mexico; Tijuana, Mexico; Guadalajara, Mexico · 13 sites in all
- A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapyPivotal-lookingCompleted
Boryung Pharmaceutical Co., LtdIndustry
NCT01258673 · 263 participants · Start Nov 2010 · Primary completion Dec 2011
Drug: Fimasartan/HCTZ combination; Fimasartan · For: Essential Hypertension
Sites: Sungnam, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Comparative Cardiovascular Outcomes of Fimasartan and Calcium Channel Blockers in Hypertension: A Nationwide 3-Year Follow-Up Cohort Study.
Ahn Y, Lee JI, Jeong HS, et al. · J Clin Med 2026
- Emerging Pharmacological Therapies for Hypertension.
Mahajan P, Pagar A, Baviskar K, et al. · Curr Hypertens Rev 2026
- Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study.
Youn JC, Lee SY, Yu CW, et al. · Drug Des Devel Ther 2026
- Combination of Fimasartan and Statins in Patients With Hypertension and Dyslipidemia.
Cho KH, Kim SH, Lee SR, et al. · J Lipid Atheroscler 2026
- Eco-friendly Nano-scale Bio-analytical Insights for Spectrofluorimetric Estimation of Fimasartan Using Integrated Approach of Enhanced Microwave-assisted Hantzsch Reaction and Multicolored Analytical Chemistry.
Prajapati P, Mandal P, Solanki H, et al. · J Fluoresc 2025
- Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.
Hong SJ, Kim JH, Cha KS, et al. · Clin Ther 2025
Also in development for Essential Hypertension
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- DWC202314PPhase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- Experimental: SacubitrilPhase 32 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Essential Hypertension
- AD-227APhase 31 trial
Addpharma Inc. · Essential Hypertension
- AD-227BPhase 31 trial
Addpharma Inc. · Essential Hypertension
- AD-227CPhase 31 trial
Addpharma Inc. · Essential Hypertension
- ATB-1011Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
- ATB-1012Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.